Research programme: adeno associated virus based gene therapies - Capsida Biotherapeutics/Prevail
Latest Information Update: 28 Mar 2024
At a glance
- Originator Capsida Biotherapeutics; Prevail Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 31 Jul 2023 Sangoma Therapeutics entered into R&D agreement with Prevail Therapeutics to develop adeno associated virus based gene therapies which affect the central nervous system (CNS) (SANGAMO Therapeutics SEC 2024)
- 04 Jan 2023 Capsida Biotherapeutics entered into R&D agreement with Prevail Therapeutics (subsidiary of Eli Lilly and Company) to develop transformative genetic medicines for serious diseases which affect the central nervous system (CNS)
- 04 Jan 2023 Early research in CNS disorders in USA (Parenteral)